×

The push back on Sovaldi

2:52 PM ET Fri, 25 July 2014

Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.